Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn)
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
tildrakizumab-asmn
Sun Pharma presents insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis
Reportedly, updated cost analysis reveals ILUMYA is among the most cost-effective first-line treatments for moderate-to-severe…